#dividends

#dividends

Accounts for Jamie Oliver Holdings (JOH) show pre-tax profits dropped from £3.4 million to £2.4 million in 2024, despite a 6% rise in sales to £28.6 million. The results reflect a mixed year for the celebrity chef's media and restaurant group, which saw strong growth in hospitality offset by lower income from media and brand deals. JOH encompasses Oliver's television and publishing ventures, endorsements, cookery school, and restaurant operations, as well as licensing and franchise income from international Jamie's Italian and Jamie's Deli outlets.

Dividend-oriented strategies aren't just for traditional value investors anymore. Many investors want to capture artificial intelligence (AI) growth while still generating reliable income. That can be achieved by pairing income-focused ETFs with AI-heavy funds, creating a forward-looking portfolio that balances payouts with exposure to transformative technology. Why Combine Dividends With AI? Artificial intelligence is reshaping industries from healthcare and finance to entertainment and manufacturing. Companies such as Nvidia, Microsoft, Alphabet, and AMD are leading this shift.

BAB Inc (BABB) is a franchise business operating casual eateries that sell bagels, muffins, and coffee. It does not operate the stores directly, making money by licensing brands.

The S&P 500 has delivered an average annual return of approximately 10.33% since 1957, serving as a benchmark for many investors.

UnitedHealth (NYSE:UNH) is a Dividend Aristocrat trading at 2018 prices after a slew of unfortunate events that caused it to plunge. The December assassination of CEO Brian Thompson rattled investors and triggered an internal succession scramble, followed immediately by a rare 1.2% earnings miss in Q1, a guidance withdrawal, and the group's CEO resigning.

Microsoft's commitment to AI capital expenditures of $80 billion raises questions among investors about the potential for higher dividend yields amidst strong cash flow.

General Mills trades at a TTM P/E of 12.2, yielding 4.81%, making it an attractive option for income-focused investors amidst market volatility.

Bristol-Myers Squibb, down over 42% from its peak, is becoming an attractive buy due to its high dividend yield and potential for turnaround.